#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Dydrogesterone – clinical benefits of its metabolic neutrality


Authors: Tomáš Fait
Authors‘ workplace: Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
Published in: Prakt Gyn 2015; 19(3): 155-158
Category: Gynecology and Obstetrics: Review Article

Overview

Progestagens have oferent biologic affects which must be included into therapeutic choice. The best progestogen for the hormone replacement therapy could be metabolic neutral and safe for breast tissue. Micronised progesterone and dydrogesterone have better safety profile than synthetic progestagens. Also during pregnancy we prefer natural gestagens to synthetic ones.

Key words:
dydrogesterone – early pregnancy loss – hormone replacement therapy – menstrual cycle disturbance – preterm labor


Sources

1. Raghupathy R, Al Mutawa E, Makhseed M et al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG 2005; 112(8): 1096–1101. Erratum in BJOG 2005; 112(11): 1585.

2. Omar MH, Mashita MK., LIM PS., Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 2005; 97(5): 421–425.

3. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012; 28(12): 983–990.

4. El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005; 97(5): 431–434.

5. Fait T, Zikán M, Mašata J. Moderní farmakoterapie v gynekologii a porodnictví. Maxdorf: Praha 2014. ISBN 978–80–7345–403–6.

6. Carmichael SL, Shaw GM, Laurent C et al. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005; 159(10): 957–962.

7. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115(7): 840–845.

8. De Villiers TJ, Pines A, Panay N et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16(3): 316–337.

9. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103–111.

10. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obst Gyn 2009; 113(1): 65–73 

11. Santen R, Allred DC, Ardoin SP et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95(7 Suppl1): S1–S66.

12. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions PEPI Trial. JAMA 1996; 275(5): 370–375.

13. Schindler AE, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl 1): S7-S16.

14. Druckmann R. Individuelle Hormonsubstitution: die Rolle der Gestagene. Journal für Menopause 2002; 9 (Sonderheft 2) (Ausgabe für Schweiz): 4–5. Journal für Menopause 2002; 9 (Sonderheft 2) (Ausgabe für Deutschland): 4–5.

15. Fournier A, Fabre A, Mesrine S. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008; 26(8): 1260–1268.

16. Ziel HK, Finkle WD. Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens. N Engl J Med 1975; 293(23): 1167–1170.

17. Grady D, Gebretsadik T, Kerlikowske K et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85(2): 304–313.

Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#